What is the optimal patient selection for combined androgen ablative and radiation therapy? The role of combined modality staging.

Abstract

The 5-year results of neoadjuvant androgen suppression and external beam radiation therapy for locally advanced prostate cancer show a benefit in local, distant, and biochemical control when compared with external beam radiation therapy alone. Further follow-up will ascertain if these findings translate into a survival benefit. Combined modality staging is… (More)

Topics

  • Presentations referencing similar topics